July 2026 in “Applied Sciences” This review suggests that 308 nm excimer therapy may offer a well-tolerated non-pharmacologic option for alopecia areata, with more limited evidence for its effectiveness in lichen planopilaris and frontal fibrosing alopecia.
May 2026 in “International Journal of Molecular Sciences” This review highlights emerging evidence that chemotherapy-induced alopecia may be driven by immune mechanisms similar to alopecia areata, involving hair follicle immune privilege collapse, and evaluates Janus kinase inhibitors as potential treatments, while cautioning about their immunosuppressive risks in cancer patients.
January 2026 in “Aging and Disease” This review discusses recent research on the Dickkopf protein family's involvement in non-cancerous diseases and considers their potential as biomarkers and therapeutic targets without presenting new experimental results.
December 2025 in “International Journal of Molecular Sciences” This review examined 40 studies on exosome-based therapies for alopecia areata, reporting significant hair regrowth and improvements in hair count, length, and thickness, but highlighted the need for standardized methodologies and robust RCTs before clinical application.
December 2025 in “Cosmetics” This review synthesizes recent molecular and preclinical advances in alopecia areata and androgenetic alopecia, highlighting how interventions targeting specific intracellular signaling pathways and utilizing stem cell technologies can support precision regrowth and structural follicle reconstruction.
November 2025 in “Biomedicines” This study found that the JAK1 inhibitors baricitinib and abrocitinib significantly reduced mechanical alloknesis in a murine model of atopic dermatitis, whereas the JAK2 inhibitor AZ960 had no effect.
February 2025 in “Diagnostics” In this study, JAK inhibitors significantly improved outcomes for patients with both atopic dermatitis and alopecia areata, while dupilumab was linked to worsening alopecia in some cases.
October 2024 in “Frontiers in Immunology” This study proposes that intranasal exposure to PTx and autoantigen in an animal model can trigger autoimmune disease, supporting the idea that subclinical nasal colonization by BP may cause alopecia areata.
April 2024 in “International journal of molecular sciences” This study examines the similarities and differences in the pathogenesis of autoimmune conditions alopecia areata and vitiligo, highlighting shared features like immune cell involvement and cytokine pathways, while noting differing immune responses in skin and hair.
December 2023 in “Regenerative therapy” In this review, the authors reported that exosomal miRNA-based therapies showed promising therapeutic effects on nine skin diseases in animal models, with enhanced outcomes observed when using miRNA-overexpressing exosomes compared to natural ones; however, no comparisons to standard treatments were available.
May 2022 in “Liver transplantation” This source does not report original research findings but reviews the mechanisms and challenges of immune response and immunosuppressive management in liver transplantation.
April 2019 in “Journal of Investigative Dermatology” This study found that blocking LFA-1 signaling completely prevented the development of alopecia areata in C3H/HeJ mice, suggesting that LFA-1 plays a crucial role in the disease's pathogenesis and could be a target for new therapies.
72 citations
,
March 2023 in “Biomolecules” This study reviewed the use of dupilumab, beyond its approved indications for atopic dermatitis and prurigo nodularis, and found effective treatment reports for various chronic inflammatory skin diseases such as bullous autoimmune diseases, eczema, and alopecia areata, highlighting its broad potential in dermatology.
32 citations
,
December 2017 in “Journal of the American Academy of Dermatology” Alopecia areata patients often have low vitamin D levels.
10 citations
,
July 2025 in “Stem Cell Research & Therapy” This review summarizes the mechanisms of mesenchymal stem cell-mediated wound healing and highlights engineering strategies that enhance therapeutic outcomes, but it reports no new clinical results.
9 citations
,
May 2023 in “Stem Cell Research & Therapy” This study found that mesenchymal stem cell treatment alleviated atopic dermatitis-like symptoms in a mouse model by modulating immune and inflammatory responses, with gene expression changes suggesting pathways for potential personalized treatment approaches.
5 citations
,
October 2021 in “Clinical, cosmetic and investigational dermatology” In this study, Japanese patients with alopecia areata were found to have higher BMI and retinol intake, with retinol intake predicting severity of hair loss.
1 citations
,
April 2023 in “Frontiers in Immunology” This review explored recent research on the immune mechanisms and potential therapeutic targets for alopecia areata, highlighting the roles of immune-related cells, autocrine and paracrine signaling, as well as factors like adipose-derived stem cells and gut microbiota in disease pathogenesis.
September 2025 in “International Journal of Molecular Sciences” This review reports on the potential for deucravacitinib, an oral TYK2 inhibitor approved for psoriasis, to treat various immune-mediated diseases, with emerging research suggesting possible uses in neurodegenerative diseases and certain cancers.
September 2025 in “PeerJ” This study found that the genes FCER1A and RGS1 are promising biomarkers for diagnosing systemic lupus erythematosus, with FCER1A downregulated and RGS1 upregulated in patients.
This review highlights that recent advancements in diagnostics and therapies, including AI-enhanced imaging, biomarker analysis, and novel treatments like low-dose oral minoxidil and JAK inhibitors, are improving the precision and customization of hair loss management.
49 citations
,
October 2023 in “Journal of Dermatological Science” 21 citations
,
August 2024 in “Journal of Clinical Medicine” This review highlights that malnutrition, including deficiencies in proteins and micronutrients, may exacerbate allergic conditions like dermatitis and asthma by promoting inflammation, while adequate micronutrient intake supports regulatory immune responses.
5 citations
,
April 2022 in “Evidence-based Complementary and Alternative Medicine” This study explored the mechanism of Shaoyao Gancao decoction in treating alopecia areata and found that it may be closely related to the PI3K/AKT signaling pathway.
1 citations
,
May 2025 in “The Journal of Dermatology” In this study, increased Treg cell activity indicated by IL-10 and IL-15 was identified as a feature of ADTA, distinguishing it from AA and potentially explaining ADTA's more favorable prognosis.
October 2024 in “Preprints.org” This review by two dermatologists suggests that hair on the human scalp may protect against skin cancer not just physically, but by enabling IL-17 immune surveillance, with hair loss potentially leading to increased tumor growth due to reduced immunosurveillance.
September 2024 in “Preprints.org” In this review, the authors propose that hair on the scalp may protect against non-melanoma skin cancer by maintaining an IL-17 biased immunosurveillance, with hair loss potentially increasing the risk of skin cancer due to disrupted immune monitoring.
November 2023 in “Journal of Investigative Dermatology” Adipose stem cell exosomes may effectively treat atopic dermatitis by reducing inflammation and improving skin health.
97 citations
,
May 2019 in “Frontiers in Cell and Developmental Biology” This review examines the interaction between the extracellular matrix and immune cells in skin diseases and evaluates advanced therapies that target involved molecular mechanisms, reporting no new clinical findings.
52 citations
,
December 2014 in “Journal of Dermatological Science” Apremilast may help treat hair loss in alopecia areata.